Pathway will distribute Ganeden’s patented GanedenBC30 strain, targeting food, beverage and supplement makers.

GanedenBC30 has been incorporated into about 40 products mostly in the US since 2008.

"Partnering with Pathway International is an important step in achieving our global expansion goals for 2010," said Andrew Lefkowitz, Ganeden Biotech president and chief executive officer.

Pathway managing director, Wayne Coote, said: "We look forward to a long-term relationship with Ganeden Biotech through which we can help introduce GanedenBC30 to new markets and manufacturers interested in innovative functional ingredients."